EA034783B1 - Антитело-антагонист, специфичное для гетеродимера альфа4бета7 - Google Patents

Антитело-антагонист, специфичное для гетеродимера альфа4бета7 Download PDF

Info

Publication number
EA034783B1
EA034783B1 EA201171148A EA201171148A EA034783B1 EA 034783 B1 EA034783 B1 EA 034783B1 EA 201171148 A EA201171148 A EA 201171148A EA 201171148 A EA201171148 A EA 201171148A EA 034783 B1 EA034783 B1 EA 034783B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
binding protein
antigen binding
cells
polypeptide
Prior art date
Application number
EA201171148A
Other languages
English (en)
Russian (ru)
Other versions
EA201171148A1 (ru
Inventor
Хайлин Хсу
Ян ФОЛТЦ
Таруна Арора
Фредерик У. Джекобсен
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA034783(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201171148A1 publication Critical patent/EA201171148A1/ru
Publication of EA034783B1 publication Critical patent/EA034783B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
EA201171148A 2009-03-20 2010-03-16 Антитело-антагонист, специфичное для гетеродимера альфа4бета7 EA034783B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16215409P 2009-03-20 2009-03-20
US30682910P 2010-02-22 2010-02-22
PCT/US2010/027422 WO2010107752A2 (en) 2009-03-20 2010-03-16 Alpha-4-beta-7 heterodimer specific antagonist antibody

Publications (2)

Publication Number Publication Date
EA201171148A1 EA201171148A1 (ru) 2012-04-30
EA034783B1 true EA034783B1 (ru) 2020-03-20

Family

ID=42224952

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171148A EA034783B1 (ru) 2009-03-20 2010-03-16 Антитело-антагонист, специфичное для гетеродимера альфа4бета7

Country Status (26)

Country Link
US (6) US8444981B2 (enExample)
EP (1) EP2408816B1 (enExample)
JP (3) JP5498566B2 (enExample)
KR (2) KR101391472B1 (enExample)
CN (2) CN102388068B (enExample)
AR (1) AR075882A1 (enExample)
AU (1) AU2010226814B2 (enExample)
CA (2) CA2754113C (enExample)
CL (3) CL2011002306A1 (enExample)
CO (1) CO6501170A2 (enExample)
CR (1) CR20110544A (enExample)
EA (1) EA034783B1 (enExample)
ES (1) ES2751946T3 (enExample)
IL (4) IL214868A (enExample)
JO (1) JO3615B1 (enExample)
MA (1) MA33213B1 (enExample)
MX (4) MX2011009897A (enExample)
MY (2) MY162752A (enExample)
NZ (1) NZ595464A (enExample)
PE (2) PE20120497A1 (enExample)
SG (3) SG10201801337WA (enExample)
TN (1) TN2011000433A1 (enExample)
TW (2) TWI466681B (enExample)
UY (1) UY32501A (enExample)
WO (1) WO2010107752A2 (enExample)
ZA (1) ZA201107279B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
WO2013078375A2 (en) * 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6579097B2 (ja) * 2014-02-28 2019-09-25 アステラス製薬株式会社 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
SG11201701382PA (en) 2014-08-22 2017-03-30 Sorrento Therapeutics Inc Antigen binding proteins that bind cxcr3
MA40592A (fr) 2014-10-06 2016-04-14 Chemocentryx Inc Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
KR20240149974A (ko) * 2015-08-11 2024-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 항체
MA43755A (fr) 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
KR102039189B1 (ko) * 2016-03-23 2019-11-01 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
IL270201B2 (en) 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
US12643950B1 (en) 2019-02-07 2026-06-02 Takeda Pharmaceutical Company Limited Autoinjector comprising high concentration formulation of vedolizumab
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (en) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan BIOMATERIAL SENSOR SYSTEMS
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
CA3210390A1 (en) 2021-03-12 2022-09-15 Thomas M. Moran Neutralizing monoclonal antibodies to bk virus
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content
US20260199503A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006248A2 (en) * 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
WO2001078779A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
WO2002076406A2 (en) * 2001-03-27 2002-10-03 Gershwin M Eric Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
WO2004016769A2 (en) * 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2005067620A2 (en) * 2004-01-09 2005-07-28 Pfizer Inc. ANTIBODIES TO MAdCAM
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20080299129A1 (en) * 2006-03-10 2008-12-04 Lewis Katherine E Antagonists to il-17a, il-17f, and il-23p19 and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US714785A (en) 1901-07-03 1902-12-02 Benjamin M Davis Disinfecting apparatus.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US7435802B2 (en) * 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
DE69535133T2 (de) 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
WO2002078779A1 (fr) * 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
JP2008535823A (ja) 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
US7480268B2 (en) 2005-07-28 2009-01-20 Symbol Technologies, Inc. System and method for multiprotocol wireless communication
EP1948691A1 (en) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006248A2 (en) * 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
WO2001078779A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
WO2002076406A2 (en) * 2001-03-27 2002-10-03 Gershwin M Eric Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
WO2004016769A2 (en) * 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2005067620A2 (en) * 2004-01-09 2005-07-28 Pfizer Inc. ANTIBODIES TO MAdCAM
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20080299129A1 (en) * 2006-03-10 2008-12-04 Lewis Katherine E Antagonists to il-17a, il-17f, and il-23p19 and methods of use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FEAGAN, B.G. ; GREENBERG, G.R. ; WILD, G. ; FEDORAK, R.N. ; PARE, P. ; MCDONALD, J.W.D. ; COHEN, A. ; BITTON, A. ; BAKER, J. ; DUB: "Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the @a4@b7 Integrin", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 12, 1 December 2008 (2008-12-01), AMSTERDAM, NL, pages 1370 - 1377, XP025872069, ISSN: 1542-3565, DOI: 10.1016/j.cgh.2008.06.007 *
GREEN, L.L.: "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", JOURNAL OF IMMUNOLOGICAL METHODS., ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), NL, pages 11 - 23, XP004187631, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(99)00137-4 *
RUDIKOFF S, ET AL.: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/pnas.79.6.1979 *
RUTGEERTS, P. ; VERMEIRE, S. ; VAN ASSCHE, G.: "Biological Therapies for Inflammatory Bowel Diseases", GASTROENTEROLOGY, ELSEVIER INC., US, vol. 136, no. 4, 1 April 2009 (2009-04-01), US, pages 1182 - 1197, XP026070050, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2009.02.001 *
SCHWEIGHOFFER T., ET AL.: "SELECTIVE EXPRESSION OF INTEGRIN ALPHA4BETA7 ON A SUBSET OF HUMAN CD4+ MEMORY T CELLS WITH HALLMARKS OF GUT-TROPHISM.", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 151., no. 02., 15 July 1993 (1993-07-15), US, pages 717 - 729., XP002048550, ISSN: 0022-1767 *
SOLER DULCE; CHAPMAN TOBIAS; YANG LI-LI; WYANT TIM; EGAN ROBERT; FEDYK ERIC R: "The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 330, no. 3, 1 September 2009 (2009-09-01), US, pages 864 - 875, XP009134512, ISSN: 0022-3565, DOI: 10.1124/jpet.109.153973 *
TIDSWELL M ET AL: "Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1.", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 159, no. 3, 1 August 1997 (1997-08-01), US, pages 1497 - 1505, XP002200150, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
CA2754113C (en) 2014-08-05
IL232009A (en) 2015-11-30
US8454961B2 (en) 2013-06-04
IL239965A0 (en) 2015-08-31
JP5498566B2 (ja) 2014-05-21
UY32501A (es) 2010-04-30
MX2011009897A (es) 2011-12-08
CN102388068B (zh) 2015-05-20
CA2851737A1 (en) 2010-09-23
IL232008A (en) 2015-11-30
MX357211B (es) 2018-06-29
CO6501170A2 (es) 2012-08-15
CN103382222A (zh) 2013-11-06
IL214868A0 (en) 2011-11-30
WO2010107752A3 (en) 2011-01-20
HK1168116A1 (en) 2012-12-21
US20170275365A1 (en) 2017-09-28
TWI466681B (zh) 2015-01-01
TN2011000433A1 (en) 2013-03-27
CL2011002306A1 (es) 2012-01-13
CA2851737C (en) 2019-01-08
EA201171148A1 (ru) 2012-04-30
WO2010107752A2 (en) 2010-09-23
CR20110544A (es) 2011-12-07
SG10201400798VA (en) 2014-07-30
US8454962B2 (en) 2013-06-04
US20130302354A1 (en) 2013-11-14
US20150086563A1 (en) 2015-03-26
IL232009A0 (en) 2014-05-28
CL2014000401A1 (es) 2014-08-29
NZ595464A (en) 2013-08-30
MX338969B (es) 2016-05-06
IL214868A (en) 2015-08-31
KR101391472B1 (ko) 2014-05-07
US20120177662A1 (en) 2012-07-12
ZA201107279B (en) 2012-12-27
CN102388068A (zh) 2012-03-21
JP2012520679A (ja) 2012-09-10
SG10201801337WA (en) 2018-03-28
US8871490B2 (en) 2014-10-28
IL239965A (en) 2016-10-31
AU2010226814A1 (en) 2011-09-29
MA33213B1 (fr) 2012-04-02
KR20110128948A (ko) 2011-11-30
PE20160553A1 (es) 2016-05-18
SG174344A1 (en) 2011-11-28
CL2014000400A1 (es) 2014-08-29
US20100254975A1 (en) 2010-10-07
US9499620B2 (en) 2016-11-22
ES2751946T3 (es) 2020-04-02
EP2408816B1 (en) 2019-09-04
PE20120497A1 (es) 2012-05-14
JP5980384B2 (ja) 2016-08-31
TW201418281A (zh) 2014-05-16
MX357213B (es) 2018-06-29
US20120183561A1 (en) 2012-07-19
JO3615B1 (ar) 2020-08-27
CA2754113A1 (en) 2010-09-23
AR075882A1 (es) 2011-05-04
TW201036626A (en) 2010-10-16
KR101346530B1 (ko) 2013-12-31
MX2014013424A (es) 2015-07-29
JP2015214563A (ja) 2015-12-03
MY184957A (en) 2021-04-30
TWI477511B (zh) 2015-03-21
MY162752A (en) 2017-07-14
US8444981B2 (en) 2013-05-21
CN103382222B (zh) 2016-12-28
EP2408816A2 (en) 2012-01-25
KR20130067314A (ko) 2013-06-21
AU2010226814B2 (en) 2013-05-16
IL232008A0 (en) 2014-05-28
JP5775615B2 (ja) 2015-09-09
JP2014140372A (ja) 2014-08-07

Similar Documents

Publication Publication Date Title
JP5775615B2 (ja) アルファ−４−ベータ−７ヘテロ二量体特異的アンタゴニスト抗体
US20240218076A1 (en) Therapeutic antibodies
AU2018201333B2 (en) DKK1 Antibodies And Methods Of Use
CA2662613C (en) Compositions and methods relating to glucagon receptor antibodies
DK2205635T3 (en) Antigen-binding proteins ABLE TO BIND thymic stromal lymphopoietin
TW202216757A (zh) 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法
AU2016208453B2 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
HK1187355A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
HK1168116B (en) Alpha-4-beta-7 heterodimer specific antagonist antibody

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM